Pharmaceutical Biocatalysis

Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of Catalysts.

Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes. Phosphodiesterases. Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson's Disease and Aromatic Amino Acid Decarboxylase Deficiency. Advancing Phospholipase D Enzymes as Diverse Drug Targets. IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia (AML): Current Perspectives. Enzymes for Prodrug-Activation in Cancer Treatment and Gene Therapies. Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer. β-Lactams and Related Compounds as Antibacterials and β-Lactamase Inhibitors. Non-Vitamin K Oral Anticoagulants (NOACs): New Options. Molecular Mechanisms for Statin Pleiotropy and Possible Clinical Relevance in Cardiovascular Disease. Lysosomal Storage Disorders and Enzyme Replacement Therapy.